Flow cytometry based chronologic analysis of surface glycoproteins of resting and stimulated platelets in normal individuals

Pakistan Journal of Medical Sciences

Volumn 28, Issue 4, 2012, Pages

  Saboor, Muhammad ^a   Moinuddin, M ^a   Ilyas, Samina ^a  

^a BAQAI MEDICAL UNIVERSITY   (Pakistan)

Author keywords

CD62P; CD63; Flow cytometry; Incubation; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; CD61 ANTIGEN; CD63 ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PADGEM PROTEIN;

ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INCUBATION TIME; LIPOPROTEIN BLOOD LEVEL; MALE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

EID: 84863438097     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mylotte D, Foley D, Kenny D. Platelet function testing: methods of assessment and clinical utility. Cardiovasc Hematol Agents Med Chem 2011;9(1):14-24.
2. Pakala R, Waksman R. Currently available methods for platelet function analysis: advantages and disadvantages. Cardiovasc Revasc Med 2011;12(5):312-322.
3. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009;102:248-257.
4. Puddu P, Muscari A, Puddu GM, Cravero E, Giannoni C, Zoli M. The complexity of platelet metabolism and its contribution to atherothrombosis. Acta Cardiol 2009;64:157-165.
5. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378-3384.
6. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther 2009;14:157-169.
7. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-1834.
8. Harrison P. Platelet function analysis. Blood Rev 2005;1:111-123.
9. Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy. Semin Thromb Hemost 2005;31(4):393-399.
10. Kenneth A Ault. The clinical utility of flow cytometry in the study of platelets. Seminars in hematology 2001;38(2)160-168.
11. Linden MD, Frelinger AL, Barbard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004;30(5):501-511.
12. Harrison P. Assessment of platelet function in the laboratory. Hamostaseologie 2009;29(1):25-31.
13. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001;104:1533-1537.
14. Sbrana S, Della Pina F, Rizza A, Buffa M, De Filippis R, Gianetti J. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADPinduced platelet activation. Cytometry B Clin Cytom 2008;74(1):30-39.
15. Cox D. Methods for monitoring platelet function. Am Heart J 1998;135:S160-S169.
16. Michelson AD, Furman MI. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 1999;6(5):342-348.
17. Buggle F, Mayer H, Marquardt GL, Ruf A, Mansmann U, Winter R. Course of platelet activation markers after ischemic stroke. Stroke 2002;33:2570-2574.
18. van der Zee PM, Biro E, Ko Y, de Winter RJ, Hack CE, Sturk A, et al. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem 2006;52(4):657-664.
19. Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to extent of disease and platelet activation markers. Ann Med 2005;37(1):61-66.
20. Chang I, Choudhury A, Patel J, Lip GY. Soluble, plateletbound and total P-selectin as indices of platelet activation in congestive heart failure. Ann Med 2009;41(1):45-51.
21. Belniak-Legiec E, Stelmasiak Z. Blood platelet activation markers in patients with acute cerebral infarction during the earliest stage of the disease-evaluation using flow cytometry methods. Neurol Neurochir Pol 2000;34(5):853-864.
22. Cha JK, Jo WS, Shin HC, Bae HR, Ho JM, Kim JW. Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke. Platelets 2004;15(1):3-7.
23. Tsai NW, Chang WN, Shaw CF, Jan CR, Chang HW, Huang CR, et al. Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res 2009;124(2):213-218.
24. Matzdroff AC, Kuhnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J Lab Clin Med 2000;135:247-255.
25. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface p-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996;93:11877-11882.